AVD-104 yielded sustained vision improvements in patients with geographic atrophy, with no statistical difference reported in the rate of change in GA area vs. monthly avacincaptad pegol, according to a press release.The phase 2a SIGLEC trial randomly …
ORLANDO — In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib presented at Eyecelerator@AAO.“We’ve always known that vorolanib was a potent inhibitor of all the VEGF receptors,” Duker …
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the controversy surrounding FDA-approved treatments for geographic atrophy.Two treatments are commercially available, but Kim, professor of ophtha…
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses GLP-1 drugs and their retinal side effects.GLP-1s can cause rapid progression of diabetic retinopathy, Kim said, and there are increasing concerns…
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses excitement about the use of AI in retina practices.Possible applications of AI include rendering opinions on care and screening patients.“Right no…
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the toxicity of drugs such as Plaquenil.“In this modern day, we should never be seeing patients who lose vision from Plaquenil (hydroxychloroquine…